2024 saw a wealth of clinical progression with Nouscom, CureVac, Transgene and other pioneering companies paving the way for neoantigen based vaccines and therapies to become tolerable, durable medicines to effectively treat cancer.
Ready to unite the global neoantigen community, the 8th International Neoantigen Summit 2025 returns to address key challenges in the discovery, translation and clinical development of safe and cost-effective neoantigen therapies and vaccines to attract investors and ultimately improve the health of patients.

Join neoantigen leaders from the likes of AstraZeneca, Geneos Therapeutics, Evaxion Biotech and many more at this end-to-end meeting, focusing on the development of durable, neoantigen cancer vaccines and cell therapies. With the potential to deliver safe, efficacious personalized or off-the-shelf therapeutic options to patients, this is your chance to collaborate and accelerate the translation of neoantigen-based therapies from discovery to clinical success.

To know more visit: https://ter.li/zdfjes